On January 9, 2026, shares of Beta Bionics declined sharply in trading, following the company’s disclosure of preliminary fourth-quarter 2025 performance metrics that fell short of market expectations.
The company reported lower-than-anticipated new patient starts for its iLet automated insulin delivery system, prompting investor concerns regarding near-term adoption trends and revenue growth.
On this news, Beta Bionics stock fell roughly $11.85 or 37.04% to close at $20.14, on January 9, 2026.
To learn more about the Beta Bionics investigation, go to www.faruqilaw.com/BBNX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
